Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MC4R | P32245 | 4/20 | 0.55 |
| ▸ | MC3R | P41968 | 1/20 | 0.55 |
| ▸ | MC1R | Q01726 | 1/20 | 0.55 |
| ▸ | DPP7 | Q9UHL4 | 3/20 | 0.45 |
| ▸ | DPP4 | P27487 | 2/20 | 0.45 |
| ▸ | FAP | Q12884 | 1/20 | 0.45 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.45 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.45 |
| ▸ | AKT1 | P31749 | 11/20 | 0.45 |
| ▸ | AKT2 | P31751 | 1/20 | 0.43 |
| ▸ | AKT1S1 | Q96B36 | 1/20 | 0.43 |
| ▸ | AKT3 | Q9Y243 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6476840 | 0.96 | MC4R (0.60) | MC4RMC3RMC1RDPP7DPP4 | |
| SCHEMBL6199494 | 0.95 | MC4R (0.62) | MC4RMC3RMC1RDPP7DPP4 | |
| SCHEMBL6485552 | 0.81 | MC4R (0.62) | MC4RMC3RMC1RDPP7DPP4 | |
| SCHEMBL6476091 | 0.79 | MC4R (0.70) | MC4RMC3RMC1RDPP7DPP4 | |
| SCHEMBL6476088 | 0.79 | MC4R (0.70) | MC4RMC3RMC1RDPP7DPP4 | |
| SCHEMBL6477319 | 0.78 | MC4R (0.55) | MC4RMC3RMC1RDPP4AKT1 | |
| SCHEMBL6949567 | 0.77 | MC4R (0.50) | MC4RMC3RMC1RDPP7DPP8 | |
| SCHEMBL6486410 | 0.77 | MC4R (0.56) | MC4RMC3RMC1RAKT1 | |
| SCHEMBL6483327 | 0.77 | MC4R (0.68) | MC4RMC3RMC1RDPP7DPP4 | |
| SCHEMBL6197883 | 0.77 | MC4R (0.70) | MC4RMC3RMC1RDPP7DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050239835-A1 | Melanocortin receptor ligands | EBETINO FRANK H | 2005-10-27 | — | — | US | disclosed |
| US-20040010010-A1 | Melanocortin receptor ligands | PROCTER & GAMBLE COMPANY, THE | 2004-01-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050239835-A1 | Melanocortin receptor ligands | MC1R, MC4R, MC3R | MC4R 2/4885MC3R 3/4885MC1R 1/4885 |
| US-20040010010-A1 | Melanocortin receptor ligands | MC1R, MC4R, MC5R | MC4R 2/4885MC3R 4/4885MC1R 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.